The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 10 best mid-cap stocks that could double your money.

On June 2, Vera Therapeutics, Inc. (NASDAQ:VERA) announced that it reached an agreement with the U.S. Food and Drug Administration regarding an accelerated timeline for its ORIGIN 3 eGFR analysis plan. This revised approach is intended to support the full regulatory approval of atacicept for adult patients suffering from IgA nephropathy (IgAN).

Likoper/Shutterstock.com

The third quarter of 2026 is when the eGFR findings are anticipated to be released, while in the fourth quarter of 2026, Vera plans to file a supplemental Biologics License Application (sBLA) for complete regulatory approval, contingent on the results of the data. Additionally, the modified regulatory approach was supported by past eGFR data from the company’s ORIGIN Phase 2b clinical trial.

Marshall Fordyce, M.D., the Founder and CEO of Vera Therapeutics, noted that this modification highlights the medication’s potential to be the first licensed treatment for adult IgAN patients that targets both BAFF and APRIL. He also mentioned the possibility of accelerating full market approval by advancing the data analysis timeline.

Vera Therapeutics Inc. (NASDAQ:VERA) is a late-stage clinical biotechnology company that addresses immunological conditions. The company develops and commercializes transformative treatments for serious diseases such as immunoglobulin A nephropathy. It is currently developing MAU868, which is a monoclonal antibody for BK viremia infections in transplant patients.

While we acknowledge the potential of VERA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.